SEC Investigating Illumina’s Multi-Billion Dollar Merger with GRAIL

The Securities and Exchange Commission is the latest government agency to look into Illumina’s $8 billion acquisition deal with cancer diagnostics company GRAIL, the DNA sequencing giant revealed Thursday in an SEC filing.